CLINICAL TRIALS PROFILE FOR GUANABENZ ACETATE
✉ Email this page to a colleague
All Clinical Trials for guanabenz acetate
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02423083 ↗ | Oral Guanabenz for Multiple Sclerosis | Terminated | National Institute of Neurological Disorders and Stroke (NINDS) | Phase 1 | 2015-04-21 | Background: - People with multiple sclerosis (MS) get lesions in their brain and spinal cord. These cause neurological symptoms and sometimes disability. Researchers want to see if a blood pressure drug called guanabenz can repair lesions and help people with MS. Objective: - To see if guanabenz is safe and well tolerated in people with MS. Eligibility: - People 18 55 years old with MS who have taken glatiramer acetate for the past year. Design: - Participants will be screened in a separate protocol. For 2 months, they will be examined and have magnetic resonance imaging (MRI) scans. This will decide if they are in the Stable or Active MS study group. - The study will last 5 months. There will be up to 11 visits, 5 overnight. - Visit 1: overnight stay at the clinic: - Medical history and physical exam. - Health questionnaire - Bladder ultrasound scan - Brain MRI - Electrocardiogram (EKG) to measure heart electrical activity - Blood will be drawn through an intravenous (IV) line. - Participants may have tests of strength, muscle tone, and movement. - They will get their first dose of the study drug, a tablet taken once a day. - Participants will take the study drug at home and keep a medicine diary. - The dose will slowly increase. Each time, participants will stay overnight at the clinic. They will have a physical exam, EKG, MRI, and IV blood draw. - Visit 6: Participants will have a physical exam, MRI, and blood drawn. They will get a schedule to slowly lower their drug dose and stop taking guanabenz. - Participants will have 2 final visits. They will have a physical exam, EKG, MRI, and IV blood draw. |
| NCT02443103 ↗ | Study Evaluating the Biologic Activity of Guanabenz in Bone Metastasis | Terminated | Kathy Miller | N/A | 2015-05-07 | This study will explore the biologic activity of guanabenz in reducing bone turn over in solid tumor patients with bone metastasis. If successful, this repurposing of an already, generic drug could benefit patients faster than manufacturing a novel expensive compound. |
| NCT05084404 ↗ | Efficacy and Safety of Guanabenz for Nonalcoholic Fatty Liver Disease | Not yet recruiting | Yokohama City University | Phase 2 | 2021-10-22 | To investigate the efficacy and safety of 4 mg/day of WY-8678 (guanabenz acetate) and 8 mg/day of WY-8678 (guanabenz acetate) in patients with non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH patients) with hypertension |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for guanabenz acetate
Condition Name
Clinical Trial Locations for guanabenz acetate
Trials by Country
Clinical Trial Progress for guanabenz acetate
Clinical Trial Phase
Clinical Trial Sponsors for guanabenz acetate
Sponsor Name
